Clinical trials: Dermatitis Atopic
Atopic Dermatitis, Dermatitis Atopic
Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China
This is a 16-week, open label, exploratory study designed to investigate dupilumab's effect on skin barrier function as measured by transepidermal water loss (TEWL) before and after skin tape stripping.
- Trial name
- BALISTAD-CN (NCT05624112)
- Testing
- Dupilumab
- Where
- China
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Sanofi
Atopic Dermatitis (AD)
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
The goal of this clinical trial is to learn if drug CGB-500 works to treat atopic dermatitis in subjects 12 years of age or older. It will also learn about the safety of CGB-500.
- Trial name
- NCT06923228
- Testing
- CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- CAGE Bio Inc.
Atopic Dermatitis
Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer
A unicentric, blind, non-comparative clinical study to evaluate the efficacy of a moisturizer in reducing clinical symptons of atopic dermatites in children through clinical, subjective and instrumental evaluations.
- Trial name
- NCT05530707
- Testing
- Moisturizer containing saccharide isomerate and niacinamide
- Where
- Brazil
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Farmoquimica S.A.
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Adults With Atopic Dermatitis
This is a phase 2 study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.
- Trial name
- NCT02757729
- Testing
- PAC-14028 cream 0.1%, PAC-14028 cream 0.3%, PAC-14028 cream 1.0%
- Where
- South Korea
- Volunteers
- 192 people
- Sponsor
- Amorepacific Corporation
Atopic Dermatitis
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis
This is a bridging study only for Chinese subjects. The goal of this clinical trial is to learn if drug Nemolizumab works to treat moderate to severe AD in over 12 years old male and female.
- Trial name
- NCT07762833
- Testing
- Nemolizumab 30 mg
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Galderma R&D
Atopic Dermatitis Eczema
A Safety, Tolerability and Preliminary Efficacy Study of FRTX-02 Capsules in Healthy Subjects and Subjects With Atopic Dermatitis
FRTX-02 is an orally-available, potent and selective DYRK1A inhibitor.
- Trial name
- NCT05382819
- Testing
- FRTX-02 Capsule
- Where
- Canada
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Fresh Tracks Therapeutics, Inc.
Atopic Dermatitis
Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study is to evaluate the efficacy of REGN3500 monotherapy compared with placebo treatment in adult patients with moderate-to-severe Atopic dermatitis (AD).
- Trial name
- NCT03736967
- Testing
- REGN3500, Dupilumab, REGN3500 + Dupilumab Combo
- Where
- 66 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Regeneron Pharmaceuticals
Dermatitis, Atopic
A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)
The purpose of this study is to evaluate how well JNJ-95475939 works as compared to placebo in participants with moderate to severe atopic dermatitis.
- Trial name
- DUPLEX-AD (NCT06881251)
- Testing
- Dupilumab, JNJ-95475939
- Where
- 71 sites in United States, Argentina and 7 more
- Volunteers
- 256 people
- Sponsor
- Janssen Research & Development, LLC
Dermatitis, Atopic
Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis
The aim of this study is evaluate the effect of three moisturising creams on Stratum corneum (SC) hydratation and barrier function.
- Trial name
- NCT00846235
- Testing
- Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%
- Where
- Finland
- Volunteers
- 24 people
- Sponsor
- Orion Corporation, Orion Pharma
Atopic Dermatitis, Eczema
Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.
Atopic eczema is a chronic inflammatory skin disease, mainly affecting children, characterized by itching and flare-ups. It results from genetic and environmental factors, leading to immunological and cutaneous abnormalities.
- Trial name
- NCT06756438
- Testing
- Study product
- Where
- Poland
- Volunteers
- 88 people
- Sponsor
- NAOS Les Laboratoires
Atopic Dermatitis, Asthma
Probiotics and Allergic Diseases
Many studies had demonstrated that probiotics could be applied in the prevention and adjuvant treatment for allergic diseases. In this study, we investigate the effects of Lactobacillus paracasei GMNL-133(LP), Lactobacillus…
- Trial name
- probiotics (NCT01635738)
- Testing
- LP GMNL-133 capsule, LF GM-090 capsule, LP GMNL-133 +LF GM-090 capsule
- Where
- Taiwan
- Volunteers
- 240 people
- Sponsor
- GenMont Biotech Incorporation
Atopic Dermatitis
Epiceram™ Device Versus Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) for Treatment of Atopic Dermatitis
Novel therapies for AD that avoid immunosuppression and potential carcinogensis are needed. EpiCeram™ , a topical cream, represents a novel class of therapy for skin disorders that does not contain corticosteroids or other…
- Trial name
- NCT00616538
- Testing
- Epiceram(r), Fluticasone Propionate 0.05%
- Volunteers
- 121 people
- Sponsor
- Ceragenix Pharmaceuticals
Atopic Dermatitis
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
This is a Phase 3 Double Blind multi-center study conducted at 40 investigational sites in United States to assess the efficacy and safety of Difamilast Ointment 1% in subjects ≥2 years of age with mild to moderate atopic…
- Trial name
- NCT05608343
- Testing
- Difamilast
- Where
- 39 sites in United States
- Volunteers
- 153 people
- Sponsor
- Acrotech Biopharma Inc.
Atopic Eczema
Skin Tolerance Study of Betamethasone Creams in Atopic Eczema and the Preventative Properties of a Moisturiser
Topical steroid creams as well as moisturizing creams are important parts of the treatment strategy of atopic eczema. This study aims to investigate the tolerance of a new strong steroid cream in comparison to an already marketed…
- Trial name
- NCT00576238
- Testing
- betamethasone valerate, urea
- Where
- 5 sites in Sweden
- Volunteers
- 55 people
- Sponsor
- ACO Hud Nordic AB
Atopic Dermatitis
Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis.
The purpose of this Phase Ib study is to investigate the safety, tolerability and pharmacokinetics of LEO 29102 2,5 mg/g cream when treating atopic dermatitis (AD) lesions from 10 up to 100% of the body surface area (BSA) twice…
- Trial name
- NCT01447758
- Testing
- LEO 29102, LEO 29102 Cream Vehicle
- Where
- 8 sites in Germany
- Volunteers
- 58 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
Administration for Placebo Group and Evalution the Safety and Efficacy in Atopic Dermatitis Patients
A Multi-center, Open, Single-arm Clinical Trial to Evaluate the Safety and Efficacy of FURESTEM-AD inj. in Patients with Moderate to Severe Chronic Atopic Dermatitis Who Participated in a Placebo Group in K0102 Clinical Trial…
- Trial name
- NCT04087863
- Testing
- Not applicable(observational study)
- Where
- South Korea
- Volunteers
- 99 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Atopic Dermatitis
A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis
Participants who meet eligibility criteria will be randomized in a 1:1:1 ratio to receive a twice daily oral LNK01001 dose A or LNK01001 dose B or matching placebo for 12 weeks.
- Trial name
- NCT06085521
- Testing
- LNK01001 Dose A, LNK01001 Dose B
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Lynk Pharmaceuticals Co., Ltd
Atopic Dermatitis (AD)
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
This is a randomized, double-blind, three-arm, parallel-group study designed to demonstrate the similarity of the pharmacokinetics (PK), safety, and immunogenicity of GS101 injection compared with U.S.
- Trial name
- NCT07411755
- Testing
- GS101 injection, U.S. commercial Dupixent®, CN commercial Dupixent®
- Where
- China
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Jiangsu Genscend Biopharmaceutical Co., Ltd
Atopic Dermatitis
Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis
A multicenter, randomized, double-blind, vehicle controlled phase III clinical study to evaluate the efficacy and safety of VC005 in adults and adolescents with mild to moderate atopic dermatitis
- Trial name
- NCT07592585
- Testing
- VC005
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis
A Clinical Trial of BMX-010 in Adult Subjects With Atopic Dermatitis
Phase 2 clinical trial conducted in 2 parts: Part 1 - Pharmacokinetics and Part 2 - Randomized and Placebo Controlled (subject and clinical assessors will be blinded). Study Product will be applied to AD BID days 1-28.
- Trial name
- NCT05491447
- Testing
- BMX-010
- Where
- 19 sites in United States
- Volunteers
- 103 people
- Sponsor
- BioMimetix JV, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.